# PyroGenesis Canada Inc.: overview PYRGF · OTC · CIK 1743344 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pyrgf.md) · [Financials](/companies/pyrgf/financials.md) · [Filings](/companies/pyrgf/filings.md) · [Insiders](/companies/pyrgf/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [4.8](/filings/0001104659-21-049824.md) | [17.8](/filings/0001410578-22-000806.md) | [31.1](/filings/0001562762-23-000149.md) | [19.0](/filings/0001562762-23-000149.md) | | Gross margin | % | [27.0%](/filings/0001104659-21-049824.md) | [58.0%](/filings/0001410578-22-000806.md) | [40.0%](/filings/0001562762-23-000149.md) | [42.8%](/filings/0001562762-23-000149.md) | | Operating margin | % | [(168.5%)](/filings/0001104659-21-049824.md) | [(7.3%)](/filings/0001410578-22-000806.md) | [(55.8%)](/filings/0001562762-23-000149.md) | [(122.0%)](/filings/0001562762-23-000149.md) | | Net margin | % | [(190.5%)](/filings/0001104659-21-049824.md) | [235.0%](/filings/0001410578-22-000806.md) | [(123.7%)](/filings/0001562762-23-000149.md) | [(169.2%)](/filings/0001562762-23-000149.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001104659-21-049824.md) | [0.27](/filings/0001410578-22-000806.md) | [(0.23)](/filings/0001562762-23-000149.md) | [(0.19)](/filings/0001562762-23-000149.md) | | Free cash flow | $m | [(4.1)](/filings/0001104659-21-049824.md) | [(1.5)](/filings/0001410578-22-000806.md) | [(19.6)](/filings/0001562762-23-000149.md) | [(11.5)](/filings/0001562762-23-000149.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pyrgf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HUNTINGTON NATIONAL BANK](/funds/49205.md) | 2026-06-30 | $14.5k | 100,000 | | Unchanged | ## Recent filings [All 163 filings](/companies/pyrgf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2023-11-14 | 05:53 ET | [6-K](/filings/0001171843-23-007086.md) | Report of a foreign private issuer, period 2023-09-30 | 0001171843-23-007086 | | 2023-11-09 | 12:20 ET | [6-K](/filings/0001171843-23-006965.md) | Report of a foreign private issuer, period 2023-11-09 | 0001171843-23-006965 | | 2023-11-08 | 05:21 ET | [6-K](/filings/0001171843-23-006852.md) | Report of a foreign private issuer, period 2023-11-07 | 0001171843-23-006852 | | 2023-10-30 | 05:30 ET | [6-K](/filings/0001171843-23-006523.md) | Report of a foreign private issuer, period 2023-10-27 | 0001171843-23-006523 | | 2023-10-25 | 06:02 ET | [6-K](/filings/0001171843-23-006379.md) | Report of a foreign private issuer, period 2023-10-24 | 0001171843-23-006379 | | 2023-10-11 | 03:00 ET | [6-K](/filings/0001171843-23-006202.md) | Report of a foreign private issuer, period 2023-10-11 | 0001171843-23-006202 | | 2023-10-03 | 05:32 ET | [6-K](/filings/0001171843-23-006003.md) | Report of a foreign private issuer, period 2023-10-03 | 0001171843-23-006003 | | 2023-09-19 | 13:22 ET | [6-K](/filings/0001171843-23-005789.md) | Report of a foreign private issuer, period 2023-09-19 | 0001171843-23-005789 | | 2023-09-12 | 11:44 ET | [6-K](/filings/0001171843-23-005677.md) | Report of a foreign private issuer, period 2023-09-12 | 0001171843-23-005677 | | 2023-09-05 | 07:15 ET | [6-K](/filings/0001171843-23-005555.md) | Report of a foreign private issuer, period 2023-08-31 | 0001171843-23-005555 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2022](/filings/0001562762-23-000149.md), filed Mar 31, 2023. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1743344 - Tickers: PYRGF - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A8 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.